Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.German pharmaceutical group Bayer and US partner Regeneron launched Tuesday advanced tests on a treatment for pathologic Myopia, a serious eye condition highly prevalent in Asian countries.
The two companies began so-called Phase III clinical trials in collaboration with the Singapore Eye Research Institute to determine the efficacy and safety of the product VEGF Trap-Eye, a Bayer statement said.
"With this study, we hope to show the efficacy of VEGF Trap-Eye in combating yet another important cause of vision loss, myopic choroidal neovascularization (CNV)," it quoted Bayer vice president Rupert Sandbrink as saying.
Tests have begun in Japan and are to be extended to China, Singapore, South Korea and Taiwan before authorisation for sale is sought in 2013.
People suffering from myopic CNV have "abnormal blood vessels that grow and leak blood and fluid into the retina as a result of degenerative changes in the retinal lining of the eye," the statement said.
It can eventually cause blindness, and as yet has no specific treatment, but VEGF Trap-Eye has already produced positive results with a similar disorder, neovascular (wet) age-related macular degeneration (AMD), Bayer added.
That is the main cause of blindness in elderly people, the German group said in a statement released in December
It estimated then that VEGF Trap-Eye sales could amount to 250-500 million euros ($335-670 million) per year.
Bayer shares showed a gain Tuesday of 0.81 percent to 55.75 euros in afternoon trading on the Frankfurt stock exchange, which was 0.82 percent higher overall.
etb/wai/rl
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments